Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($1.07), $0.02 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $18 million versus the consensus estimate of $15.48 million.

Cash, cash equivalents and short-term investments as of June 30, 2021 were $336.3 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.